FDA’s ‘Drug Safety Priorities’ Working Group Politicized Under Biden Administration

The FDA has been making decisions based on ideology, not drug safety.

Puberty blockers are a particularly notable case for a safety discussion, as they are used off-label to block the natural progression of biological puberty in healthy children and adolescents.

Cross-sex hormones and puberty blockers are correlated with dramatically increased (sevenfold) risks of stroke, heart attack, and blood clots.

The last two decades of puberty-blocking reports to the FDA ’s Adverse Event Reporting Database reported around 70,000 adverse event reports yet never received a solitary mention in any FDA Drug Safety Priorities report over the past decade .

The FDA needs nonpolitical, nonpartisan, and equitable monitoring of drug safety across all classes.